Accepted Manuscript

Role of MSC-derived galectin 3 in the AML microenvironment

Peter P. Ruvolo, Vivian R. Ruvolo, Jared K. Burks, YiHua Qiu, Rui-Yu Wang, Elizabeth J. Shpall, Leonardo Mirandola, Numsen Hail, Jr, Zhihong Zeng, Teresa McQueen, Naval Daver, Sean M. Post, Maurizio Chiriva-Internati, Steven M. Kornblau, Michael Andreeff



PII:	S0167-4889(18)30062-4
DOI:	doi:10.1016/j.bbamcr.2018.04.005
Reference:	BBAMCR 18267
To appear in:	
Received date:	28 November 2017
Revised date:	9 April 2018

Revised date:9 April 2018Accepted date:10 April 2018

Please cite this article as: Peter P. Ruvolo, Vivian R. Ruvolo, Jared K. Burks, YiHua Qiu, Rui-Yu Wang, Elizabeth J. Shpall, Leonardo Mirandola, Numsen Hail, Jr, Zhihong Zeng, Teresa McQueen, Naval Daver, Sean M. Post, Maurizio Chiriva-Internati, Steven M. Kornblau, Michael Andreeff, Role of MSC-derived galectin 3 in the AML microenvironment. The address for the corresponding author was captured as affiliation for all authors. Please check if appropriate. Bbamcr(2018), doi:10.1016/j.bbamcr.2018.04.005

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

ACCEPTED MANUSCRIPT

Role of MSC-derived Galectin 3 in the AML Microenvironment

Peter P. Ruvolo^{1,2}, Vivian R. Ruvolo^{1,2}, Jared K. Burks^{1,2}, YiHua Qiu^{1,2}, Rui-Yu Wang^{1,2}, Elizabeth J. Shpall³, Leonardo Mirandola⁴, Numsen Hail, Jr. ^{1,2}, Zhihong Zeng^{1,2}, Teresa McQueen^{1,2}, Naval Daver¹, Sean M. Post¹, Maurizio Chiriva-Internati^{4,5}, Steven M. Kornblau^{1,2*} and Michael Andreeff^{1,2*}

From the ¹Department of Leukemia, ²Section of Molecular Hematology, University of Texas MD Anderson Cancer Center, Houston, TX; ³Department of Stem Cell Transplantation, University of Texas MD Anderson Cancer Center, Houston, TX; ⁴Kiromic Biopharma, Houston, TX; ⁵Department of Lymphoma and Myeloma, University of Texas MD Anderson Cancer Center, Houston, TX

* These authors contributed equally to the manuscript.

Corresponding Author: Peter Ruvolo, Department of Leukemia, The University of Texas M.D. Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030. E-mail: pruvolo@mdanderson.org Download English Version:

https://daneshyari.com/en/article/8303643

Download Persian Version:

https://daneshyari.com/article/8303643

Daneshyari.com